Synthetic Biologics, Inc. (SYN)

NYSEAMERICAN: SYN · IEX Real-Time Price · USD

0.406 -0.020 (-4.69%)

Oct 22, 2021 4:00 PM EDT - Market closed

Market Cap	53.61M
Revenue (ttm)	n/a
Net Income (ttm)	-20.46M
Shares Out	132.04M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,776,974
Open	0.426
Previous Close	0.426
Day's Range	0.385 - 0.426
52-Week Range	0.283 - 1.700
Beta	1.81
Analysts	Buy
Price Target	1.88 (+363.1%)
Est. Earnings Date	Nov 9, 2021

About SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant...

IndustryBiotechnology

IPO DateJun 26, 2006

CEOSteven Shallcross

Employees10

Stock ExchangeNYSEAMERICAN

Ticker SymbolSYN

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SYN stock is "Buy." The 12-month stock price forecast is 1.88, which is an increase of 363.05% from the latest price.

Price Target

$1.88

(363.05% upside)

Analyst Consensus: Buy

News

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal A...

ROCKVILLE, Md., Oct. 21, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

2 days ago - PRNewsWire

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...

2 weeks ago - PRNewsWire

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

1 month ago - PRNewsWire

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols:AVIR HSTO NRBO NVIV PRVB

1 month ago - InvestorPlace

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be H...

ROCKVILLE, Md., Aug. 5, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

2 months ago - PRNewsWire

Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital

ROCKVILLE, Md., August 3, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

2 months ago - PRNewsWire

Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021

ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

2 months ago - PRNewsWire

3 Biotech Penny Stocks That You Need to Know About In 2021

Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other symbols:NRBO NVIV

3 months ago - PennyStocks

Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical...

ROCKVILLE, Md., June 29, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

3 months ago - PRNewsWire

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...

4 months ago - PRNewsWire

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and...

5 months ago - PRNewsWire

Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021

ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

5 months ago - PRNewsWire

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic...

ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent ...

6 months ago - PRNewsWire

Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline ...

ROCKVILLE, Md., April 1, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent a...

6 months ago - PRNewsWire

Synthetic Biologics: 6 Things for SYN Stock Investors to Know as the Biotech Skyrockets

Synthetic Biologics (SYN) stock is soaring higher on heavy trading Tuesday even without a lack of news concerning the company. The post Synthetic Biologics: 6 Things for SYN Stock Investors to Know as t...

9 months ago - InvestorPlace